The announcement was welcome news for those with major depressive disorder, affecting an estimated 8.3% of the adult ...

The U.S. Food and Drug Administration expanded approval for Johnson & Johnson's nasal spray, Spravato, to allow it to be used ...

An emerging treatment for clinical depression has reached an important milestone. This week, the Food and Drug Administration ...

Johnson & Johnson's ketamine-derived nasal spray has been approved as a standalone treatment to fight depression for those ...

"Treatment-resistant depression can be very complicated, especially for patients who do not respond to oral antidepressants ...

A multidisciplinary approach, including ketamine withdrawal and symptom management, is essential to mitigate long-term ...

The Food and Drug Administration (FDA) has approved Spravato, a nasal spray developed by Johnson & Johnson, as a standalone ...

Respondents who said they used other drugs recreationally were also likelier to say they used ketamine during the past year ...

Here's what MDs want you to know about Spravato, the latest FDA-approved standalone nasal spray for depression.

Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the ...

The following is a summary of “Intranasal racemic ketamine maintenance therapy for patients with treatment-resistant ...